EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ACADIA Pharmaceuticals's enterprise value is $2,362.8 Mil.
ACADIA Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $726.4 Mil. Therefore, ACADIA Pharmaceuticals's EV-to-Revenue for today is 3.25.
The historical rank and industry rank for ACADIA Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ACAD'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.27 Med: 18.51 Max: 24104.29
Current: 3.25
During the past 13 years, the highest EV-to-Revenue of ACADIA Pharmaceuticals was 24104.29. The lowest was 3.27. And the median was 18.51.
ACAD's EV-to-Revenue is ranked better than 69.34% of 1034
companies
in the Biotechnology industry
Industry Median: 7.69
vs ACAD: 3.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ACADIA Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, ACADIA Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's EV-to-Revenue falls into.
ACADIA Pharmaceuticals's current Enterprise Value is $2,362.8 Mil.
ACADIA Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $726.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals's share price for today is $17.2112.
ACADIA Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACAD has been successfully added to your 